Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 03, 2024

SELL
$1.59 - $1.74 $10,894 - $11,922
-6,852 Reduced 7.22%
88,020 $146,000
Q4 2023

Feb 16, 2024

BUY
$1.34 - $8.43 $127,128 - $799,770
94,872 New
94,872 $151,000

Others Institutions Holding RPHM

About Reneo Pharmaceuticals, Inc.


  • Ticker RPHM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,479,600
  • Market Cap $41.1M
  • Description
  • Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as w...
More about RPHM
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.